Do Young Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Do Young Kim has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Erin McElvania
Department of Pathology, University of Chicago, Pritzker School of Medicine
2 shared publications For The Cdc Prevention Epicenter Program
2 shared publications- Mary K. Hayden
Rush University
2 shared publications Michael Y Lin
Department of Internal Medicine, Division of Infectious Diseases, Rush University Medical Center , Chicago, Illinois , USA
2 shared publicationsNicholas M Moore
Department of Internal Medicine, Division of Infectious Diseases, Rush University Medical Center , Chicago, Illinois , USA
2 shared publications- Tristan R. Grams
Department of Pathology, University of Utah, Salt Lake City, Utah, USA
2 shared publications
Latest Publications
- Open Access
- 25 March 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1)
Molecular epidemiology and clinical differentiation between Clostridioides difficile infection and colonization across three chicago medical centers
In a retrospective cohort study at three Chicago academic medical centers, 22/81 (27.2%) patients with a clinically adjudicated positive C. difficile test result were colonized. Recent antibiotic usage predicted true infection (adjusted odds ratio: 4.38 for infection). Restriction endonuclease analysis(REA) group Y (29.3%) replaced BI (9.3%) as the dominant strain.
- 25 March 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1)
Open AccessMolecular epidemiology and clinical differentiation between Clostridioides difficile infection and colonization across three chicago medical centers
In a retrospective cohort study at three Chicago academic medical centers, 22/81 (27.2%) patients with a clinically adjudicated positive C. difficile test result were colonized. Recent antibiotic usage predicted true infection (adjusted odds ratio: 4.38 for infection). Restriction endonuclease analysis(REA) group Y (29.3%) replaced BI (9.3%) as the dominant strain.
- 23 March 2023
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 61 (3) , e0040922
Closing the Brief Case: Bergeyella zoohelcum Bacteremia in an Immunocompromised 69-Year-Old Patient
- 23 March 2023
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 61 (3) , e0040922
Closing the Brief Case: Bergeyella zoohelcum Bacteremia in an Immunocompromised 69-Year-Old Patient
- 23 March 2023
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 61 (3) , e0040822
The Brief Case: Bergeyella zoohelcum Bacteremia in an Immunocompromised 69-Year-Old Patient
A 69-year-old male with a history of metastatic prostate cancer on chemotherapy and lymphedema of bilateral lower extremities presented to the emergency department (ED) in septic shock with confusion and weakness. The patient was hypotensive (blood pressure, 69/50 mm/Hg), tachycardic (heart rate, 110 beats per minute), and tachypneic (respiratory rate, 24 breaths per minute) upon presentation to the ED. On physical examination, erythema and tenderness were observed below the left knee to above the ankle, concerning for cellulitis. Computed tomography (CT) imaging of the left lower extremity revealed prominent thickening of the subcutaneous soft tissues but did not show loculated fluid collection, ulceration, or a sinus tract. The patient was admitted to the intensive care unit (ICU) for further care.
- 23 March 2023
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 61 (3) , e0040822
The Brief Case: Bergeyella zoohelcum Bacteremia in an Immunocompromised 69-Year-Old Patient
A 69-year-old male with a history of metastatic prostate cancer on chemotherapy and lymphedema of bilateral lower extremities presented to the emergency department (ED) in septic shock with confusion and weakness. The patient was hypotensive (blood pressure, 69/50 mm/Hg), tachycardic (heart rate, 110 beats per minute), and tachypneic (respiratory rate, 24 breaths per minute) upon presentation to the ED. On physical examination, erythema and tenderness were observed below the left knee to above the ankle, concerning for cellulitis. Computed tomography (CT) imaging of the left lower extremity revealed prominent thickening of the subcutaneous soft tissues but did not show loculated fluid collection, ulceration, or a sinus tract. The patient was admitted to the intensive care unit (ICU) for further care.
- Open Access
- 31 October 2022
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 9 (11) , ofac581
Genomic Investigation to Identify Sources of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Healthcare Personnel in an Acute Care Hospital
Background: Identifying the source of healthcare personnel (HCP) coronavirus disease 2019 (COVID-19) is important to guide occupational safety efforts. We used a combined whole genome sequencing (WGS) and epidemiologic approach to investigate the source of HCP COVID-19 at a tertiary-care center early in the COVID-19 pandemic.Methods: Remnant nasopharyngeal swab samples from HCP and patients with polymerase chain reaction–proven COVID-19 from a period with complete sample retention (14 March 2020 to 10 April 2020) at Rush University Medical Center in Chicago, Illinois, underwent viral RNA extraction and WGS. Genomes with >90% coverage underwent cluster detection using a 2 single-nucleotide variant genetic distance cutoff. Genomic clusters were evaluated for epidemiologic linkages, with strong linkages defined by evidence of time/location overlap.Results: We analyzed 1031 sequences, identifying 49 clusters that included ≥1 HCP (265 patients, 115 HCP). Most HCP infections were not healthcare associated (88/115 [76.5%]). We did not identify any strong epidemiologic linkages for patient-to-HCP transmission. Thirteen HCP cases (11.3%) were attributed to a potential patient source (weak evidence involving nonclinical staff that lacked location data to prove or disprove contact with patients in same cluster). Fourteen HCP cases (12.2%) were attributed to HCP source (11 with strong evidence).Conclusions: Using genomic and epidemiologic data, we found that most HCP severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections were not healthcare associated. We did not find strong evidence of patient-to-HCP transmission of SARS-CoV-2.
- 31 October 2022
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 9 (11) , ofac581
Open AccessGenomic Investigation to Identify Sources of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Healthcare Personnel in an Acute Care Hospital
Background: Identifying the source of healthcare personnel (HCP) coronavirus disease 2019 (COVID-19) is important to guide occupational safety efforts. We used a combined whole genome sequencing (WGS) and epidemiologic approach to investigate the source of HCP COVID-19 at a tertiary-care center early in the COVID-19 pandemic.Methods: Remnant nasopharyngeal swab samples from HCP and patients with polymerase chain reaction–proven COVID-19 from a period with complete sample retention (14 March 2020 to 10 April 2020) at Rush University Medical Center in Chicago, Illinois, underwent viral RNA extraction and WGS. Genomes with >90% coverage underwent cluster detection using a 2 single-nucleotide variant genetic distance cutoff. Genomic clusters were evaluated for epidemiologic linkages, with strong linkages defined by evidence of time/location overlap.Results: We analyzed 1031 sequences, identifying 49 clusters that included ≥1 HCP (265 patients, 115 HCP). Most HCP infections were not healthcare associated (88/115 [76.5%]). We did not identify any strong epidemiologic linkages for patient-to-HCP transmission. Thirteen HCP cases (11.3%) were attributed to a potential patient source (weak evidence involving nonclinical staff that lacked location data to prove or disprove contact with patients in same cluster). Fourteen HCP cases (12.2%) were attributed to HCP source (11 with strong evidence).Conclusions: Using genomic and epidemiologic data, we found that most HCP severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections were not healthcare associated. We did not find strong evidence of patient-to-HCP transmission of SARS-CoV-2.
- Open Access
- 24 May 2022
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 76 (3) , e416-e425
Duration of Replication-Competent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Shedding Among Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)
Patterns of shedding replication-competent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in severe or critical COVID-19 are not well characterized. We investigated the duration of replication-competent SARS-CoV-2 shedding in upper and lower airway specimens from patients with severe or critical coronavirus disease 2019 (COVID-19). We enrolled patients with active or recent severe or critical COVID-19 who were admitted to a tertiary care hospital intensive care unit (ICU) or long-term acute care hospital (LTACH) because of COVID-19. Respiratory specimens were collected at predefined intervals and tested for SARS-CoV-2 using viral culture and reverse transcription–quantitative polymerase chain reaction (RT-qPCR). Clinical and epidemiologic metadata were reviewed. We collected 529 respiratory specimens from 78 patients. Replication-competent virus was detected in 4 of 11 (36.3%) immunocompromised patients up to 45 days after symptom onset and in 1 of 67 (1.5%) immunocompetent patients 10 days after symptom onset (P = .001). All culture-positive patients were in the ICU cohort and had persistent or recurrent symptoms of COVID-19. Median time from symptom onset to first specimen collection was 15 days (range, 6–45) for ICU patients and 58.5 days (range, 34–139) for LTACH patients. SARS-CoV-2 RNA was detected in 40 of 50 (80%) ICU patients and 7 of 28 (25%) LTACH patients. Immunocompromise and persistent or recurrent symptoms were associated with shedding of replication-competent SARS-CoV-2, supporting the need for improving respiratory symptoms in addition to time as criteria for discontinuation of transmission-based precautions. Our results suggest that the period of potential infectiousness among immunocompetent patients with severe or critical COVID-19 may be similar to that reported for patients with milder disease.
- 24 May 2022
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 76 (3) , e416-e425
Open AccessDuration of Replication-Competent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Shedding Among Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)
Patterns of shedding replication-competent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in severe or critical COVID-19 are not well characterized. We investigated the duration of replication-competent SARS-CoV-2 shedding in upper and lower airway specimens from patients with severe or critical coronavirus disease 2019 (COVID-19). We enrolled patients with active or recent severe or critical COVID-19 who were admitted to a tertiary care hospital intensive care unit (ICU) or long-term acute care hospital (LTACH) because of COVID-19. Respiratory specimens were collected at predefined intervals and tested for SARS-CoV-2 using viral culture and reverse transcription–quantitative polymerase chain reaction (RT-qPCR). Clinical and epidemiologic metadata were reviewed. We collected 529 respiratory specimens from 78 patients. Replication-competent virus was detected in 4 of 11 (36.3%) immunocompromised patients up to 45 days after symptom onset and in 1 of 67 (1.5%) immunocompetent patients 10 days after symptom onset (P = .001). All culture-positive patients were in the ICU cohort and had persistent or recurrent symptoms of COVID-19. Median time from symptom onset to first specimen collection was 15 days (range, 6–45) for ICU patients and 58.5 days (range, 34–139) for LTACH patients. SARS-CoV-2 RNA was detected in 40 of 50 (80%) ICU patients and 7 of 28 (25%) LTACH patients. Immunocompromise and persistent or recurrent symptoms were associated with shedding of replication-competent SARS-CoV-2, supporting the need for improving respiratory symptoms in addition to time as criteria for discontinuation of transmission-based precautions. Our results suggest that the period of potential infectiousness among immunocompetent patients with severe or critical COVID-19 may be similar to that reported for patients with milder disease.